Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study
November 19, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
October 13, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
NovaSignal Secures $37 Million in Series C1
September 28, 2021 09:07 ET
|
NovaSignal Corporation
LOS ANGELES, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health, announced today it has closed...
PathMaker Neurosystems Announces Completion of Pivotal European Clinical Trial Evaluating MyoRegulator® for the Non-Invasive Treatment of Post-Stroke Spasticity
September 27, 2021 05:00 ET
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, Sept. 27, 2021 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc., (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company’s DMT Program at the International Microdose DMT Conference
September 09, 2021 11:46 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
GNT Pharma Announces Approval of IND Application for the Phase III RODIN Trial of Nelonemdaz for Acute Ischemic Stroke Patients
September 08, 2021 06:00 ET
|
GNT Pharma Co., Ltd
PIII Study for 496 ischemic stroke patients treated with endovascular thrombectomyFirst multi-target neuroprotectant for the intervention of ischemic brain injurySafety and efficacy verified in two...
Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose
September 07, 2021 07:30 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy
June 23, 2021 09:00 ET
|
RapidPulse, Inc
MIAMI, June 23, 2021 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced the closing of a $15...
Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021
June 17, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that all...
The Worldwide Neurovascular Devices/Interventional Neurology Industry is Expected to Reach $3.8 Billion by 2026 at a CAGR of 8.6% from 2021
June 10, 2021 05:53 ET
|
Research and Markets
Dublin, June 10, 2021 (GLOBE NEWSWIRE) -- The "Global Neurovascular Devices/Interventional Neurology Market by Product (Embolization (Coil, Flow Diverter), Stents, Balloon Occlusion Devices, Clot...